MCID: HYP730
MIFTS: 58

Hypogonadotropic Hypogonadism

Categories: Bone diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Hypogonadotropic Hypogonadism

MalaCards integrated aliases for Hypogonadotropic Hypogonadism:

Name: Hypogonadotropic Hypogonadism 12 12 38 15 74
Klinefelter's Syndrome 12 77 54 26 44 15 17
Klinefelter Syndrome 12 54 26 45 74
Xxy Syndrome 12 54 26
Xxy Trisomy 12 26 74
47,xxy Syndrome 54 26
Congenital Idiopathic Hypogonadotropic Hypogonadism 12
Isolated Congenital Gonadotropin Deficiency 12
Hypogonadism, Hypogonadotropic 41
Klinefelters Syndrome 56

Classifications:



External Ids:

Disease Ontology 12 DOID:0090070 DOID:1921
KEGG 38 H00255
ICD9CM 36 758.7
MeSH 45 D007713
NCIt 51 C34752
SNOMED-CT 69 22053006

Summaries for Hypogonadotropic Hypogonadism

NIH Rare Diseases : 54 Klinefelter syndrome (KS) is a condition that occurs in males when they have an extra X chromosome. Some males with KS have no obvious signs or symptoms while others may have varying degrees of cognitive, social, behavioral, and learning difficulties. Adults with Klinefelter syndrome may also have primary hypogonadism (decreased testosterone production), small and/or undescendent testes (cryptorchidism), enlarged breast tissue (gynecomastia), tall stature, and/or inability to have biological children (infertility), as well as an abnormal opening of the penis (hypospadias), and an small penis (micropenis). KS is not inherited, but usually occurs as a random event during the formation of reproductive cells (eggs and sperm) that results in the presence of one extra copy of the X chromosome in each cell (47,XXY).  KS treatment is based on the signs and symptoms present in each person. Life expectancy is usually normal and many people with KS have normal life. There is a very small risk of developing breast cancer and other conditions such as a chronic inflammatory disease called systemic lupus erythematosus.  In some cases, there is more than one X chromosome in each cell (for example, 48,XXXY or 49,XXXXY). These conditions, which are often called "variants of Klinefelter" syndrome usually have more serious problems (intellectual disability, skeletal problems, and poor coordination) than classic Klinefelter syndrome (47,XXY).

MalaCards based summary : Hypogonadotropic Hypogonadism, also known as klinefelter's syndrome, is related to hypogonadotropic hypogonadism 23 without anosmia and hypogonadotropic hypogonadism 7 with or without anosmia. An important gene associated with Hypogonadotropic Hypogonadism is XIST (X Inactive Specific Transcript), and among its related pathways/superpathways are GnRH signaling pathway and Neuroactive ligand-receptor interaction. The drugs Menotropins and Anastrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and bone, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Disease Ontology : 12 A hypogonadism characterized by a impaired signalling by gonadotrpin relasing hormone.

MedlinePlus : 44 Klinefelter syndrome (KS) is a condition that occurs in men who have an extra X chromosome. The syndrome can affect different stages of physical, language, and social development. The most common symptom is infertility. Boys may be taller than other boys their age, with more fat around the belly. After puberty, KS boys may have Smaller testes and penis Breast growth Less facial and body hair Reduced muscle tone Narrower shoulders and wider hips Weaker bones Decreased sexual interest Lower energy KS males may have learning or language problems. They may be quiet and shy and have trouble fitting in. A genetic test can diagnose KS. There is no cure, but treatments are available. It is important to start treatment as early as possible. With treatment, most boys grow up to have normal lives. Treatments include testosterone replacement therapy and breast reduction surgery. If needed, physical, speech, language, and occupational therapy may also help. NIH: National Institute of Child Health and Human Development

Wikipedia : 77 Klinefelter syndrome (KS) also known as 47,XXY or XXY, is the set of symptoms that result from two or... more...

Related Diseases for Hypogonadotropic Hypogonadism

Diseases related to Hypogonadotropic Hypogonadism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 478)
# Related Disease Score Top Affiliating Genes
1 hypogonadotropic hypogonadism 23 without anosmia 34.3 GNRH1 GNRHR
2 hypogonadotropic hypogonadism 7 with or without anosmia 33.6 DUSP6 FGF17 FGFR1 GNRH1 GNRHR POLR3B
3 hypogonadotropism 32.0 GNRH1 GNRHR KISS1 KISS1R
4 normosmic congenital hypogonadotropic hypogonadism 30.6 ANOS1 CHD7 DUSP6 FGF17 FGF8 FGFR1
5 precocious puberty 30.5 GNRH1 KISS1 KISS1R
6 kallmann syndrome 30.2 ANOS1 CHD7 DUSP6 FGF17 FGF8 FGFR1
7 central precocious puberty 30.0 GNRH1 KISS1 KISS1R
8 charge syndrome 29.8 ANOS1 CHD7 FGF8 FGFR1 PROK2 PROKR2
9 cryptorchidism, unilateral or bilateral 29.6 ANOS1 FGFR1 GNRH1 GNRHR PROK2 PROKR2
10 idiopathic central precocious puberty 29.3 KISS1 KISS1R TAC3 TACR3
11 hypogonadism 27.8 ANOS1 CHD7 DUSP6 FGF17 FGF8 FGFR1
12 hypogonadotropic hypogonadism 1 with or without anosmia 12.8
13 hypogonadotropic hypogonadism 21 with or without anosmia 12.8
14 hypogonadotropic hypogonadism 10 with or without anosmia 12.8
15 hypogonadotropic hypogonadism 8 with or without anosmia 12.8
16 hypogonadotropic hypogonadism 20 with or without anosmia 12.8
17 hypogonadotropic hypogonadism 4 with or without anosmia 12.8
18 hypogonadotropic hypogonadism 11 with or without anosmia 12.8
19 hypogonadotropic hypogonadism 12 with or without anosmia 12.8
20 hypogonadotropic hypogonadism 13 with or without anosmia 12.8
21 hypogonadotropic hypogonadism 9 with or without anosmia 12.8
22 hypogonadotropic hypogonadism 14 with or without anosmia 12.8
23 hypogonadotropic hypogonadism 17 with or without anosmia 12.8
24 hypogonadotropic hypogonadism 19 with or without anosmia 12.8
25 hypogonadotropic hypogonadism 5 with or without anosmia 12.8
26 hypogonadotropic hypogonadism 2 with or without anosmia 12.8
27 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 12.7
28 hypogonadotropic hypogonadism 15 with or without anosmia 12.7
29 hypogonadotropic hypogonadism 16 with or without anosmia 12.7
30 hypogonadotropic hypogonadism 3 with or without anosmia 12.7
31 hypogonadotropic hypogonadism 22 with or without anosmia 12.7
32 hypogonadotropic hypogonadism 6 with or without anosmia 12.7
33 hypogonadotropic hypogonadism 18 with or without anosmia 12.7
34 leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism 12.7
35 hypogonadotropic hypogonadism 24 without anosmia 12.6
36 gordon holmes syndrome 12.3
37 adrenal hypoplasia, congenital 12.3
38 boucher-neuhauser syndrome 12.3
39 hypogonadotropic hypogonadism-severe microcephaly-sensorineural hearing loss-dysmorphism syndrome 12.3
40 multicore myopathy with mental retardation, short stature, and hypogonadotropic hypogonadism 12.2
41 hypogonadotropic hypogonadism-frontoparietal alopecia syndrome 12.2
42 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 12.2
43 moebius syndrome-axonal neuropathy-hypogonadotropic hypogonadism syndrome 12.2
44 ataxia - hypogonadism - choroidal dystrophy 12.2
45 bosma arhinia microphthalmia syndrome 12.1
46 polr3-related leukodystrophy 12.1
47 isolated gonadotropin-releasing hormone deficiency 11.9
48 chudley rozdilsky syndrome 11.8
49 hemochromatosis, type 1 11.7
50 48,xxxy syndrome 11.6

Graphical network of the top 20 diseases related to Hypogonadotropic Hypogonadism:



Diseases related to Hypogonadotropic Hypogonadism

Symptoms & Phenotypes for Hypogonadotropic Hypogonadism

MGI Mouse Phenotypes related to Hypogonadotropic Hypogonadism:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.13 CHD7 FGF8 FGFR1 FSHB GNRH1 GNRHR
2 growth/size/body region MP:0005378 10.03 CHD7 DUSP6 FGF8 FGFR1 GNRH1 GNRHR
3 digestive/alimentary MP:0005381 9.97 CHD7 FGF8 FGFR1 GNRH1 GNRHR KISS1
4 homeostasis/metabolism MP:0005376 9.97 CHD7 DUSP6 FGF8 FGFR1 FSHB GNRH1
5 nervous system MP:0003631 9.7 CHD7 FGF17 FGF8 FGFR1 GNRH1 KISS1
6 reproductive system MP:0005389 9.44 CHD7 FGF8 FGFR1 FSHB GNRH1 GNRHR

Drugs & Therapeutics for Hypogonadotropic Hypogonadism

Drugs for Hypogonadotropic Hypogonadism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menotropins Approved Phase 4,Not Applicable 9002-68-0, 61489-71-2 5360545
2
Anastrozole Approved, Investigational Phase 4,Phase 1 120511-73-1 2187
3
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0, 481-30-1 10204 6013
4
Polyestradiol phosphate Approved Phase 4,Not Applicable 28014-46-2
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-28-2 5757
6
Zinc Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 7440-66-6 32051
7
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
8
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
9
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
10
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
11
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
12 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Chorionic Gonadotropin Phase 4,Phase 3,Phase 2,Not Applicable
15 Follicle Stimulating Hormone Phase 4,Phase 3,Phase 2,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1
22 Aromatase Inhibitors Phase 4,Phase 3,Phase 1
23 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Bone Density Conservation Agents Phase 4,Phase 2
25 Estradiol 3-benzoate Phase 4,Not Applicable
26 Estradiol 17 beta-cypionate Phase 4,Not Applicable
27 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Anabolic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 insulin Phase 4,Phase 1,Phase 2,Not Applicable
31 Insulin, Globin Zinc Phase 4,Phase 1,Phase 2,Not Applicable
32 Hypoglycemic Agents Phase 4,Phase 1,Phase 2,Not Applicable
33 Calciferol Phase 4,Phase 2
34 Vitamins Phase 4,Phase 2
35 Trace Elements Phase 4,Phase 2
36 Micronutrients Phase 4,Phase 2
37 Mitogens Phase 4
38 Nutrients Phase 4,Phase 2
39 Analgesics, Opioid Phase 4
40 Pharmaceutical Solutions Phase 4,Phase 2,Not Applicable
41
Sodium Citrate Approved, Investigational Phase 3,Phase 2,Phase 1 68-04-2
42
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
43
Calcium Approved, Nutraceutical Phase 3,Phase 2 7440-70-2 271
44
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 77-92-9 311
45
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 8001-79-4
46
Enclomiphene Investigational Phase 3,Phase 2,Phase 1 15690-57-0
47 Prolactin Release-Inhibiting Factors Phase 3,Phase 2,Not Applicable
48 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
49 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
50 Anticoagulants Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism Unknown status NCT02880280 Phase 4 Human Menopausal Gonadotropin;Human Chorionic Gonadotropin
2 Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Unknown status NCT02310074 Phase 4 Pulsatile Gonadotropin Releasing Hormone;Human chorionic gonadotropin;Urinary Follicle-Stimulating Hormone
3 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4 Lutropin alfa;Follitropin alfa and Lutropin alfa
4 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
5 Sequential Therapy for Hypogonadotropic Hypogonadism Completed NCT01403532 Phase 4 Traditional intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH plus zinc
6 Effects of Medications in Patients With Hypogonadism Completed NCT01601327 Phase 4 Testosterone enanthate (Sustanon 250 mg);Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU);Testosteron gel (Testojel 50 mg)
7 The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism Completed NCT01533129 Phase 4 Testogel 50 mg transdermal gel;Testosterone 250mg injection
8 Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment Completed NCT02111434 Phase 4 Testosterone
9 Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy Completed NCT02171390 Phase 4 Testosterone 250mg injection;Testosteron 50 mg transdermal gel
10 The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111473 Phase 4 Testosterone
11 The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
12 Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism Completed NCT01107067 Phase 4 Sustanon
13 Testosterone Replacement in Men With Diabetes and Obesity Completed NCT01127659 Phase 4 testosterone;placebo
14 Severe LH Suppressed Patients After Administration of a GnRH Antagonist Completed NCT01936077 Phase 4 Recombinant LH (Luveris)
15 Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism Completed NCT01160341 Phase 4 Testosteron
16 Testosterone Therapy in Hypogonadal Men Treated With Opioids Recruiting NCT02433730 Phase 4 Testosterone;placebo
17 Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism Recruiting NCT03490513 Phase 4 anastrozole (1 mg/day);Placebo
18 TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY Recruiting NCT03325647 Phase 4 Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution;Placebo injectable saline
19 Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment Active, not recruiting NCT02408445 Phase 4 testosterone cypionate 200mg/ml
20 Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH) Not yet recruiting NCT03687606 Phase 4 Human Chorionic Gonadotropin;human menopausal gonadotropin
21 Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L]) Terminated NCT00328926 Phase 4 Luveris® 75 IU;Luveris® 25 IU;Placebo;Recombinant human follicle stimulating hormone (r-hFSH);Recombinant human chorionic gonadotropin (r-hCG)
22 LutrePulse Hypogonadotropic Hypogonadism Completed NCT01976728 Phase 3 Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump;Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump;Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump;Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
23 Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Completed NCT00962637 Phase 3 Androxal;Androxal;AndroGel;Placebo
24 Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism Completed NCT01067365 Phase 3 Androxal;Androxal
25 Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism Completed NCT01739595 Phase 3 enclomiphene citrate;Placebo
26 Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism Completed NCT01532414 Phase 3 Androxal;Placebo
27 A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937) Completed NCT01709331 Phase 3 Corifollitropin alfa;hCG
28 An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism Completed NCT01739582 Phase 3 Androxal
29 Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism Completed NCT01534208 Phase 3 Androxal
30 A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism Completed NCT01084265 Phase 3 Recombinant human luteinizing hormone (r-hLH);Recombinant human follicle-stimulating hormone (r-hFSH);Human chorionic gonadotropin (hCG)
31 A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% Completed NCT01993225 Phase 3 Androxal 12.5 mg/25 mg;Placebo Capsules;AndroGel 1.62%;Placebo Gel
32 A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% Completed NCT01993212 Phase 3 Androxal 12.5 mg or 25 mg;AndroGel 1.62%;Placebo Capsules;Placebo Gel
33 Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism Completed NCT01619683 Phase 3 enclomiphene citrate;Placebo
34 Short-term Effects of Aromatase Inhibition in Obese Men Completed NCT00138710 Phase 3 Letrozole (Femara)
35 Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions Completed NCT02110368 Phase 3 Testosterone Topical Gel, 1.62% Metered Pump;AndroGel (testosterone gel) 1.62% Metered-Dose Pump
36 Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men Completed NCT00467870 Phase 3 Testosterone Undecanoate 750 mg;Testosterone Undecanoate 1000 mg
37 Androgen for Leydig Cell Proliferation Completed NCT01206270 Phase 2, Phase 3 Testosterone undecanoate;Castor Oil
38 Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) Active, not recruiting NCT03019575 Phase 3 Corifollitropin alfa;hCG
39 Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men Unknown status NCT02443090 Phase 2 fispemifene
40 Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism Completed NCT02730169 Phase 2 BGS649;Placebo
41 A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene Completed NCT02651688 Phase 2 Placebo;12.5 mg Enclomiphene Citrate;25 mg Enclomiphene Citrate
42 To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone Completed NCT00706719 Phase 2 25 mg Androxal;Testim 1%
43 Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus Completed NCT01191320 Phase 2 Placebo;Androxal
44 Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism Completed NCT01270841 Phase 2 Placebo;topical testosterone;Androxal
45 Effect of Intranasal Insulin on LH Concentrations in Man Completed NCT02154477 Phase 1, Phase 2 intranasal insulin;placebo (intranasal saline)
46 Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Completed NCT00697814 Phase 2 Clomiphene citrate
47 A 6 Month Safety Extension Study of MBGS205 Completed NCT02908074 Phase 2 BGS649
48 The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone) Completed NCT01386606 Phase 2 Androxal (enclomiphene citrate);Testosterone
49 A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203 Completed NCT01386567 Phase 2 Androxal (enclomiphene citrate);Testim (topical testosterone)
50 Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism Completed NCT00193661 Phase 2 Testosterone Gel (1%)

Search NIH Clinical Center for Hypogonadotropic Hypogonadism

Cochrane evidence based reviews: klinefelter syndrome

Genetic Tests for Hypogonadotropic Hypogonadism

Anatomical Context for Hypogonadotropic Hypogonadism

MalaCards organs/tissues related to Hypogonadotropic Hypogonadism:

42
Breast, Testes, Bone, Pituitary, Brain, Liver, Endothelial

Publications for Hypogonadotropic Hypogonadism

Articles related to Hypogonadotropic Hypogonadism:

(show top 50) (show all 1549)
# Title Authors Year
1
Investigation of treatment for azoospermia due to male hypogonadotropic hypogonadism in Japan. ( 30302833 )
2019
2
Gonadotropin replacement in male thalassemia major patients with arrested puberty and acquired hypogonadotropic hypogonadism (AAH): preliminary results and potential factors affecting induction of spermatogenesis. ( 30298384 )
2019
3
Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth. ( 30629183 )
2019
4
Physical activity counteracts metabolic syndrome-induced hypogonadotropic hypogonadism and erectile dysfunction in the rabbit. ( 30645174 )
2019
5
Evidence for a Common Genetic Origin of Classic and Milder Adult-Onset Forms of Isolated Hypogonadotropic Hypogonadism. ( 30669598 )
2019
6
Clinical Management of Congenital Hypogonadotropic Hypogonadism. ( 30698671 )
2019
7
High frequency of CHD7 mutations in congenital hypogonadotropic hypogonadism. ( 30733481 )
2019
8
Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects. ( 30851011 )
2019
9
Reversible male hypogonadotropic hypogonadism due to energy deficit. ( 30903626 )
2019
10
Three Siblings with Idiopathic Hypogonadotropic Hypogonadism in a Nonconsanguineous Family: A Novel KISS1R/GPR54 Loss-of-Function Mutation ( 30905142 )
2019
11
Management of Ovulation Induction and Intrauterine Insemination in Infertile Patients with Hypogonadotropic Hypogonadism. ( 30930300 )
2019
12
Whole Exome Sequencing Revealed a Novel Nonsense Variant in the GNRHR Gene Causing Normosmic Hypogonadotropic Hypogonadism in a Pakistani Family. ( 30947225 )
2019
13
Screening for mutations in selected miRNA genes in hypogonadotropic hypogonadism patients. ( 30999277 )
2019
14
Possible role of androgen receptor gene in therapeutic response of infertile men with hypogonadotropic hypogonadism. ( 31030566 )
2019
15
Evaluation of gonadotropin-replacement therapy in male patients with hypogonadotropic hypogonadism. ( 31062720 )
2019
16
Nonstop mutation in the Kisspeptin 1 receptor (KISS1R) gene causes normosmic congenital hypogonadotropic hypogonadism. ( 31073722 )
2019
17
Corrigendum to "Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome" [Clin. Immunol. 168 (2016) 25-29]. ( 29195081 )
2018
18
Evaluating CHARGE syndrome in congenital hypogonadotropic hypogonadism patients harboring CHD7 variants. ( 29144511 )
2018
19
Klinefelter's syndrome with lupus encephalitis and retroperitoneal teratoma. ( 29759049 )
2018
20
The role of ADAMTS4 and ADAMTS9 in cardiovascular disease in premature ovarian insufficiency and idiopathic hypogonadotropic hypogonadism. ( 30187439 )
2018
21
Targeted Gene Panel Sequencing for Molecular Diagnosis of Kallmann Syndrome and Normosmic Idiopathic Hypogonadotropic Hypogonadism. ( 30216942 )
2018
22
Hypogonadotropic Hypogonadism and Kleefstra Syndrome due to a Pathogenic Variant in the EHMT1 Gene: An Underrecognized Association. ( 30370152 )
2018
23
Assessing Sex Steroid Influence on Kisspeptin Responsiveness in Idiopathic Hypogonadotropic Hypogonadism. ( 30430143 )
2018
24
Xanthomatous hypophysitis causing hypogonadotropic hypogonadism resulting in delayed presentation of slipped capital femoral epiphysis. ( 30450996 )
2018
25
Assisted reproductive techniques with congenital hypogonadotropic hypogonadism patients: a systematic review and meta-analysis. ( 30453944 )
2018
26
Prevalence and associated phenotypes of PLXNA1 variants in normosmic and anosmic idiopathic hypogonadotropic hypogonadism. ( 30467832 )
2018
27
Recombinant Human FSH Treatment Outcomes in Five Boys With Severe Congenital Hypogonadotropic Hypogonadism. ( 30519672 )
2018
28
Hypogonadotropic hypogonadism and pituitary hypoplasia as recurrent features in Ulnar-Mammary syndrome. ( 30550377 )
2018
29
The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. ( 30569789 )
2018
30
PROKR2 mutations in idiopathic hypogonadotropic hypogonadism: selective disruption of the binding to a Gα-protein leads to biased signaling. ( 30576231 )
2018
31
Testosterone undecanoate supplementation together with human chorionic gonadotropin does not impair spermatogenesis in males with isolated hypogonadotropic hypogonadism: a retrospective study. ( 30604694 )
2018
32
Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. ( 29108899 )
2018
33
Split hand/foot malformation: a potential clue to underlying FGFR1 mutation in patients with isolated congenital hypogonadotropic hypogonadism. ( 29146774 )
2018
34
FGFR1 disruption identified by whole genome sequencing in a male with a complex chromosomal rearrangement and hypogonadotropic hypogonadism. ( 29160040 )
2018
35
DCC/NTN1 complex mutations in patients with congenital hypogonadotropic hypogonadism impair GnRH neuron development. ( 29202173 )
2018
36
GENETICS IN ENDOCRINOLOGY: Genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. ( 29330225 )
2018
37
Congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty have distinct genetic architectures. ( 29419413 )
2018
38
Health-related physical fitness and quality of life in men with congenital hypogonadotropic hypogonadism. ( 29430665 )
2018
39
Infertility treatment strategy involving combined freeze-all embryos and single vitrified-warmed embryo transfer during hormonal replacement cycle for in vitro fertilization of women with hypogonadotropic hypogonadism. ( 29436143 )
2018
40
Semen quality in patients with pituitary disease and adult-onset hypogonadotropic hypogonadism. ( 29514896 )
2018
41
Predictive factors for pituitary response to pulsatile GnRH therapy in patients with congenital hypogonadotropic hypogonadism. ( 29516878 )
2018
42
Deficiency in GnRH receptor trafficking due to a novel homozygous mutation causes idiopathic hypogonadotropic hypogonadism in three prepubertal siblings. ( 29777911 )
2018
43
Transition of Care from Childhood to Adulthood: Congenital Hypogonadotropic Hypogonadism. ( 29886503 )
2018
44
MRI of ectopic posterior pituitary gland with dysgenesis of pituitary stalk in a patient with hypogonadotropic hypogonadism. ( 29887929 )
2018
45
Hypogonadotropic Hypogonadism in Men With Diabesity. ( 29934480 )
2018
46
Mutation profiles and clinical characteristics of Chinese males with isolated hypogonadotropic hypogonadism. ( 30098700 )
2018
47
Evaluation of Sexual Function in Women with Hypogonadotropic Hypogonadism Using the Female Sexual Function Index (FSFI) and the Beck Depression Inventory (BDI). ( 30099473 )
2018
48
Testicular morphology in hypogonadotropic hypogonadism after the abuse of anabolic steroids. ( 30175397 )
2018
49
Bone mineral density in older patients with never-treated congenital hypogonadotropic hypogonadism. ( 28577250 )
2018
50
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH). ( 28882981 )
2018

Variations for Hypogonadotropic Hypogonadism

Expression for Hypogonadotropic Hypogonadism

Search GEO for disease gene expression data for Hypogonadotropic Hypogonadism.

Pathways for Hypogonadotropic Hypogonadism

Pathways related to Hypogonadotropic Hypogonadism according to KEGG:

38
# Name Kegg Source Accession
1 GnRH signaling pathway hsa04912
2 Neuroactive ligand-receptor interaction hsa04080
3 Regulation of actin cytoskeleton hsa04810

Pathways related to Hypogonadotropic Hypogonadism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 ANOS1 DUSP6 FGF17 FGF8 FGFR1 FSHB
2
Show member pathways
13.09 FSHB GNRH1 GNRHR KISS1 KISS1R PROK2
3
Show member pathways
11.91 FGF17 FGF8 FGFR1 GNRH1
4
Show member pathways
11.85 ANOS1 FGF17 FGF8 FGFR1
5
Show member pathways
11.75 FGF17 FGF8 FGFR1 GNRH1
6
Show member pathways
11.45 FGF17 FGF8 FGFR1
7 11.36 FGF17 FGF8 FGFR1 GNRH1
8 9.91 FSHB GNRH1 GNRHR

GO Terms for Hypogonadotropic Hypogonadism

Cellular components related to Hypogonadotropic Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 ANOS1 FGF17 FGF8 FGFR1 FSHB GNRH1

Biological processes related to Hypogonadotropic Hypogonadism according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 FGF17 FGF8 FGFR1 FSHB PROK2
2 response to organic cyclic compound GO:0014070 9.72 DUSP6 FGF8 GNRH1
3 female pregnancy GO:0007565 9.7 FSHB GNRH1 TAC3
4 MAPK cascade GO:0000165 9.67 DUSP6 FGF17 FGF8 FGFR1
5 aorta morphogenesis GO:0035909 9.54 CHD7 FGF8
6 generation of neurons GO:0048699 9.49 FGF8 FGFR1
7 gonad development GO:0008406 9.48 FGF8 NR0B1
8 male sex determination GO:0030238 9.46 GNRH1 NR0B1
9 neuropeptide signaling pathway GO:0007218 9.46 KISS1R PROK2 PROKR2 TAC3
10 branching involved in salivary gland morphogenesis GO:0060445 9.43 FGF8 FGFR1
11 inner ear morphogenesis GO:0042472 9.43 CHD7 FGF8 FGFR1
12 organ induction GO:0001759 9.4 FGF8 FGFR1
13 tachykinin receptor signaling pathway GO:0007217 9.32 TAC3 TACR3
14 G protein-coupled receptor signaling pathway GO:0007186 9.28 FSHB GNRH1 GNRHR KISS1 KISS1R PROK2
15 fibroblast growth factor receptor signaling pathway GO:0008543 9.26 ANOS1 FGF17 FGF8 FGFR1

Molecular functions related to Hypogonadotropic Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor binding GO:0005104 8.62 FGF17 FGF8

Sources for Hypogonadotropic Hypogonadism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....